Join Drs. An de Vriese and Muh Geot Wong in a case-based discussion on optimizing long-term kidney outcomes in patients with IgA nephropathy (IgAN). Faculty review the new KDIGO guidelines, including more aggressive treatment targets such as proteinuria levels below 0.3 g/day. A clinical case is used to illustrate practical guideline application, highlighting the use of sparsentan in a patient with persistent proteinuria despite RAASi therapy. The faculty also explore combination treatment approaches, including SGLT2 inhibitors, and reference data from the SPARTAN and SPARTACUS studies.